Product category: Diagnostic agents / kits for tumour marker determination
NPC-REAAD™ is an in-vitro diagnostic intended for qualitative and semi-qualitative detection of IgA antibodies in human serum samples for nasopharyngeal carcinoma. It uses proprietary proteins developed by Restalyst to identify specific IGA antibody to EA seromarker segment. Detection of EA is associated with higher specificity in comparison to other EBV related markers, resulting in lesser false positive during screening. This is particularly important and is a feature that our customers especially value with NPC-REAAD™. Lesser false positive results reduce unnecessary worry to patients and the requirement for them to undergo unnecessary procedures or treatments.
About Nasopharyngeal Carcinoma
Nasopharyngeal Carcinoma (NPC) is a commonly diagnosed head and neck malignancy in Southeast Asia.It also occurs more frequently amongst males than females. Epstein-Barr virus is a knowncommon cause of infectious mononucleosis. After recovering, the EBV remains latent within the patient’s body and patients become life-long carriers. Studies have shown that Epstein Barr Virus (EBV) can result in cancerous nasopharynx cells, however this relationship is yet to be fully understood. EBV is one of the many contributing factors of NPC, which also includes genetics, dietary and other environmental factors.
About Internal Assessment Program
All customers are offered membership of our Internal Assessment Program. Participating laboratories can use the program to ensure continuous high quality NPC testing performance. This is the only NPC related program currently available in the region.
Overview Restalyst Pte Ltd. is a privately owned Biosciences company that offers customers proprietary, ultrasensitive protein detection products for the measurement of existing and novel biomarkers at low levels currently not possible with other existing technologies.
Mission We aim to advance disease diagnosis and treatment by developing ultrasensitive protein detection products that will allow the detection of disease earlier. In doing this, we believe that the possibility of successful outcomes in patients will be improved significantly. We are committed to our people, R&D and providing value to both customers and stakeholders.